Losartan inhibits EGFR transactivation in vascular smooth muscle cells

Background/aim: Angiotensin II (Ang II)-induced molecular signaling pathways play a significant role in the progression of cardiovascular diseases, including hypertension and atherosclerosis. In addition to the well-known effects of Ang II, it may activate epidermal growth factor receptor (EGFR) in a process known as transactivation, which contributes to vascular pathologies. The aim of this study was to determine whether losartan could reduce EGFR transactivation induced by Ang II. Additionally, we evaluated the roles of heparin-binding epidermal-like growth factor (HB-EGF) and matrix metalloproteinases (MMPs) in Ang II-induced EGFR transactivation. Materials and methods: Vascular smooth muscle cells were isolated from a rat aorta and grown in primary culture. Ang II-induced EGFR phosphorylation (tyrosine 1068) and ERK1/2 MAPK phosphorylation (threonine 202 and tyrosine 204) were evaluated by western blotting. Results: Ang II induced EGFR phosphorylation through the Ang II type I receptor (P < 0.05). The transactivation process was inhibited by losartan and mediated by HB-EGF and MMPs. Ang II transactivates EGFR in an AT1R-dependent manner. Conclusion: The results of this study show that losartan, a widely used antihypertensive agent, can suppress EGFR phosphorylation (Y1068) upon Ang II stimulation in vascular smooth muscle cells. EGFR inhibition is a candidate therapy for combating cardiovascular diseases such as hypertension and atherosclerosis.

Keywords:

Angiotensin II, EGF receptor, losartan, transactivation, extracellular regulated kinase vascular smooth muscle, cardiovascular disease,

PDF

___

Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res 2016; 118: 535-546.
Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res 2016; 118: 692-702.
Vukelic S, Griendling KK. Angiotensin II, from vasoconstrictor to growth factor: a paradigm shift. Circ Res 2014; 114: 754-757.
Das S, Senapati P, Chen Z, Reddy MA, Ganguly R, Lanting L, Mandi V, Bansal A, Leung A, Zhang S et al. Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells. Nat Commun 2017; 8: 1467.
Kumar R, Singh VP, Baker KM. The intracellular renin- angiotensin system: a new paradigm. Trends Endocrin Met 2007; 18: 208-214.
Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. Angiotensin II and vascular injury. Curr Hypertens Rep 2014; 16: 431.
Chen J, Chen JK, Neilson EG, Harris RC. Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J Am Soc Nephrol 2006; 17: 1615-1623.
Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K, Eguchi S. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscl Thromb Vas 2006; 26: e133-137.
Yang X, Zhu MJ, Sreejayan N, Ren J, Du M. Angiotensin II promotes smooth muscle cell proliferation and migration through release of heparin-binding epidermal growth factor and activation of EGF-receptor pathway. Mol Cells 2005; 20: 263-270.
Ge L, Zhang G, You B, Cheng G, Chen L, Shi R. The role of losartan in preventing vascular remodeling in spontaneously hypertensive rats by inhibition of the H2O2/VPO1/HOCl/ MMPs pathway. Biochem Bioph Res Co 2017; 493: 855-861.
Makki N, Thiel KW, Miller FJ. The epidermal growth factor receptor and its ligands in cardiovascular disease. Int J Mol Sci 2013; 14: 20597-20613.
Dreux AC, Lamb DJ, Modjtahedi H, Ferns GA. The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis 2006; 186: 38- 53.
Takahashi M, Hayashi K, Yoshida K, Ohkawa Y, Komurasaki T, Kitabatake A, Ogawa A, Nishida W, Yano M, Monden M et al. Epiregulin as a major autocrine/paracrine factor released from ERK- and p38 MAPK-activated vascular smooth muscle cells. Circulation 2003; 108: 2524-2529.
Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004; 109: 2792- 2800.
Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005; 97: 434-442.
Zeboudj L, Giraud A, Guyonnet L, Zhang Y, Laurans L, Esposito B, Vilar J, Chipont A, Papac-Milicevic N, Binder CJ et al. Selective EGFR (epidermal growth factor receptor) deletion in myeloid cells limits atherosclerosis. Arterioscl Thromb Vas 2018; 38: 114-119.
Peng K, Tian X, Qian Y, Skibba M, Zou C, Liu Z, Wang J, Xu Z, Li X, Liang G. Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II. J Cell Mol Med 2016; 20: 482-494.
Wang L, Huang Z, Huang W, Chen X, Shan P, Zhong P, Khan Z, Wang J, Fang Q, Liang G et al. Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress. Sci Rep-UK 2017; 7: 45917.
Forrester SJ, Kawai T, Elliott KJ, O’Brien S, Thomas W, Harris RC, Eguchi S. EGFR transactivation: mechanisms, pathophysiology and potential therapies in cardiovascular system. Annu Rev Pharmacol 2016; 56: 627-653.
Cetin A, Ozturk OH, Tokay A, Akcit F, Caglar S, Yesilkaya A. Angiotensin II-induced MAPK phosphorylation mediated by Ras and/or phospholipase C-dependent phosphorylations but not by protein kinase C phosphorylation in cultured rat vascular smooth muscle cells. Pharmacology 2007; 79: 27-33.
Vukelic S, Griendling KK. Angiotensin II, from vasoconstrictor to growth factor: a paradigm shift. Circ Res 2014; 114: 754-757.
Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein- coupled receptors. Nature 1996; 379: 557-560.
Wang Z. Transactivation of epidermal growth factor receptor by G protein-coupled receptors: recent progress, challenges and future research. Int J Mol Sci 2016; 17: 95.
Sandoval YH, Li Y, Anand-Srivastava MB. Transactivation of epidermal growth factor receptor by enhanced levels of endogenous angiotensin II contributes to the overexpression of Gialpha proteins in vascular smooth muscle cells from SHR. Cell Signal 2011; 23: 1716-1726.
Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 2001; 276: 7957-7962.
Akhtar S, Yousif MHM, Chandrasekhar B, Benter IF. Activation of Egfr/Erbb2 via pathways involving Erk1/2, p38 Mapk, Akt and Foxo enhances recovery of diabetic hearts from ischemia- reperfusion injury. PLoS One 2012; 7: e39066.
Muslin AJ. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci 2008; 115: 203-218.
Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci 2007; 112: 417-428.
Bokemeyer D, Schmitz U, Kramer HJ. Angiotensin II-induced growth of vascular smooth muscle cells requires an Src- dependent activation of the epidermal growth factor receptor. Kidney Int 2000; 58: 549-558.
Mugabe BE, Yaghini FA, Song CY, Buharalioglu CK, Waters CM, Malik KU. Angiotensin II-induced migration of vascular smooth muscle cells is mediated by p38 mitogen-activated protein kinase-activated c-Src through spleen tyrosine kinase and epidermal growth factor receptor transactivation. J Pharmacol Exp Ther 2010; 332: 116-124.